AquaBounty Technologies Announces First Quarter 2025 Financial Results
First Quarter 2025 Highlights
Net income for the quarter ended March 31, 2025 was $401 thousand compared to a net loss of $11.3 million for the quarter ended March 31, 2024. Included in net income 2025 was a non-cash gain of $2.0 million on the forgiveness of an outstanding loan.
On February 11, 2025, the Company completed the sale of certain equipment originally intended for its farm in Pioneer, Ohio ("Ohio Equipment Assets") for net proceeds of $2.3 million and recognized a net gain on the sale of $307 thousand.
On March 3, 2025, the Company completed the sale of its Canadian subsidiary, including the broodstock farms on Prince Edward Island, Canada ("Canadian Farms") and the Company's intellectual property for its genetically engineered Atlantic salmon, along with trademarks and patents ("Corporate IP"), for net proceeds of $1.9 million.
Cash, cash equivalents and restricted cash totaled $1.4 million as of March 31, 2025, as compared to $230 thousand as of December 31, 2024.
"As stated in our previous announcement, AquaBounty plans to continue to work with our investment banker to assess strategic alternatives for our partially constructed farm in Pioneer, Ohio ("Ohio Farm Project") and to market and sell available Ohio Equipment Assets to generate cash," commented David Frank, Chief Financial Officer and Interim Chief Executive Officer. "On February 11, 2025, we completed the sale of certain Ohio Equipment Assets that had been purchased for our Ohio Farm Project for net proceeds of $2.3 million, after deducting commissions and fees. On March 3, 2025, we completed the sale of our Canadian Farms, including the Company's Corporate IP, for net proceeds of $1.9 million, after deducting commissions, fees and the assumption of $3.2 million in outstanding loans. These transactions have provided us with the liquidity to continue to pursue strategic alternatives for our Ohio Farm Project."
"We will continue to keep all stakeholders apprised of our progress," concluded Frank.
About AquaBounty
At AquaBounty Technologies, Inc. (NASDAQ: AQB), we are a pioneer in land-based aquaculture. We have located our land-based recirculating aquaculture system farm close to key consumption markets and designed it to prevent disease and to include multiple levels of fish containment to protect wild fish populations. For more information on AquaBounty, please visit www.aquabounty.com.
Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995, as amended, including regarding the wind down of the Company's farming operations and its ability to sell available assets. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these statements because they involve significant risks and uncertainties about AquaBounty. AquaBounty may use words such as "continue," "believe," "will," "may," "expect," the negative forms of these words and similar expressions to identify such forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: our history of net losses and the likelihood of future net losses; our ability to continue as a going concern; our ability to raise additional funds, including from the sale of non-current assets, in sufficient amounts on a timely basis, on acceptable terms, or at all; our ability to retain and reengage key vendors and engage additional vendors, as needed; our ability to obtain approvals and permits to construct and operate our farms without delay; our ability to finance our Ohio Farm Project through the placement of municipal bonds, which may require restrictive debt covenants that could limit our control over the farm's operation and restrict our ability to utilize any cash that the farm generates; risks related to potential strategic acquisitions, investments or mergers; risks of disease outbreaks in Atlantic salmon farming; our ability to efficiently and cost-effectively produce and sell salmon at large commercial scale; security breaches, cyber-attacks and other disruptions could compromise our information, or expose us to fraud or liability, or interrupt our operations; any further write-downs of the value of our assets; business, political, or economic disruptions or global health concerns; adverse developments affecting the financial services industry; our ability to use net operating losses and other tax attributes, which may be subject to certain limitations; volatility in the price of our shares of common stock; our ability to maintain our listing on the Nasdaq Stock Market LLC; an active trading market for our common stock may not be sustained; our status as a "smaller reporting company" and a "non-accelerated filer" may cause our shares of common stock to be less attractive to investors; any issuance of preferred stock with terms that could dilute the voting power or reduce the value of our common stock; provisions in our corporate documents and Delaware law could have the effect of delaying, deferring, or preventing a change in control of us; our expectation of not paying cash dividends in the foreseeable future; and other risks and uncertainties discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Forward-looking statements speak only as of the date hereof, and, except as required by law, AquaBounty undertakes no obligation to update or revise these forward-looking statements. For information regarding the risks faced by us, please refer to our public filings with the SEC, available on the Investors section of our website at www.aquabounty.com and on the SEC's website at www.sec.gov.
Company & Investor Contact:AquaBounty Technologiesinvestors@aquabounty.com
Media Contact:Vince McMorrowFahlgren Mortine(614) 906-1671vince.mcmorrow@Fahlgren.com
AquaBounty Technologies, Inc.Consolidated Balance Sheets(Unaudited)
As of
March 31, 2025
December 31, 2024
Assets
Current assets:
Cash and cash equivalents
$
1,366,328
$
230,362
Prepaid expenses and other current assets
1,207,023
292,018
Current assets held for sale
4,148,500
10,819,909
Total current assets
6,721,851
11,342,289
Property, plant and equipment, net
22,668,000
22,668,000
Right of use assets, net
44,589
51,509
Total assets
$
29,434,440
$
34,061,798
Liabilities and stockholders' equity
Current liabilities:
Accounts payable and accrued liabilities
$
10,079,353
$
10,104,853
Accrued employee compensation
960,332
977,088
Current debt
1,092,641
1,261,039
Other current liabilities
29,110
28,527
Current liabilities held for sale
287,290
3,830,041
Total current liabilities
12,448,726
16,201,548
Long-term lease obligations
15,479
22,982
Long-term debt, net
—
1,996,558
Total liabilities
12,464,205
18,221,088
Commitments and contingencies
Stockholders' equity:
Common stock, $0.001 par value, 75,000,000 shares authorized; 3,869,361 and 3,865,778 shares outstanding at March 31, 2025 and December 31, 2024, respectively
3,869
3,866
Additional paid-in capital
386,337,769
386,297,611
Accumulated other comprehensive loss
—
(688,229)
Accumulated deficit
(369,371,403)(369,772,538)
Total stockholders' equity
16,970,235
15,840,710
Total liabilities and stockholders' equity
$
29,434,440
$
34,061,798
AquaBounty Technologies, Inc.Consolidated Statements of Operations and Comprehensive Loss(Unaudited)
Three Months EndedMarch 31,
2025
2024
Costs and expenses
Sales and marketing
$
6,613
$
63,633
Research and development
—
73,850
General and administrative
1,560,436
2,389,234
Gain on asset sales, net
(306,886)
—
Total costs and expenses
1,260,163
2,526,717
Operating loss
(1,260,163)
(2,526,717)
Other income (expense)
Interest expense
(133,650)
(181,241)
Loan forgiveness
2,008,046
—
Other expense, net
(4,469)
(2,447)
Total other income (expense)
1,869,927
(183,688)
Income (loss) from continuing operations
609,764
(2,710,405)
Loss from discontinued operations
(208,629)
(8,447,843)
Net income (loss)
$
401,135
$
(11,158,248)
Other comprehensive income (loss)
Foreign currency translation gain (loss)
688,229
(116,307)
Comprehensive income (loss)
$
1,089,364
$
(11,274,555)
Basic and diluted net income (loss) per share
from continuing operations
$
0.16
$
(0.70)
from discontinued operations
(0.05)
(2.19)
Total basic and diluted net income (loss) per share
$
0.10
$
(2.90)
Weighted average number of common shares
- basic and diluted
3,866,733
3,849,248
AquaBounty Technologies, Inc.Consolidated Statements of Cash Flows(Unaudited)
Three Months EndedMarch 31,
2025
2024
Operating activities
Net income (loss)
$
401,135
$
(11,158,248)
Adjustment to reconcile net income (loss) to net cash used in
operating activities:
Depreciation and amortization
—
575,544
Share-based compensation
40,161
105,155
Long-lived asset impairment
—
4,265,000
Loan forgiveness
(2,008,046)
—
Other non-cash items
—
3,390
Changes in operating assets and liabilities:
Inventory
—
1,257,290
Prepaid expenses and other assets
(518,245)
441,015
Accounts payable and accrued liabilities
(259,975)
147,831
Accrued employee compensation
(16,756)
(52,903)
Net cash used in operating activities
(2,361,726)
(4,415,926)
Investing activities
Purchases of and deposits on property, plant and equipment
—
(1,125,954)
Proceeds from asset sales
3,721,116
—
Net cash provided by (used in) investing activities
3,721,116
(1,125,954)
Financing activities
Proceeds from issuance of debt
—
117,292
Repayment of term debt
(232,194)
(184,019)
Net cash used in financing activities
(232,194)
(66,727)
Effect of exchange rate changes on cash, cash equivalents and restricted cash
8,770
(2,795)
Net change in cash, cash equivalents and restricted cash
1,135,966
(5,611,402)
Cash, cash equivalents and restricted cash at beginning of period
230,362
9,203,869
Cash, cash equivalents and restricted cash at end of period
$
1,366,328
$
3,592,467
Reconciliation of cash, cash equivalents and restricted cash reported
in the consolidated balance sheet:
Cash and cash equivalents
$
1,366,328
$
2,592,467
Restricted cash
—
1,000,000
Total cash, cash equivalents and restricted cash
$
1,366,328
$
3,592,467
Supplemental disclosure of cash flow information and non-cash transactions:
Interest paid in cash from continuing operations
$
—
$
177,851
Interest paid in cash from discontinued operations
$
16,903
$
27,322
Property and equipment included in accounts payable and accrued liabilities
$
9,137,864
$
11,453,584
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252256
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
7 minutes ago
- Yahoo
More Americans are driving to Canada than Canadians to the U.S., report finds
More American travellers drove to Canada in July than Canadians did to the United States, according to a new report by Statistics Canada. This is the first time such a reversal has taken place since before the COVID-19 pandemic. The dramatic decline of Canadians travelling to the U.S. was sparked last year, with U.S. President Donald Trump's heated rhetoric about Canada becoming the 51st state that led to an ongoing trade war and lingering tension between the two countries. The data for last month shows that 1.8 million American residents drove to Canada, compared to the 1.7 million Canadian residents who made a return trip from the U.S. by car. Canadian road trips to U.S. plunge for seventh month as boycott continues Both countries saw a decline at land border crossings last month. For Americans driving to Canada, there was a slight dip of 7.4 per cent compared to the same month last year. It was also the sixth consecutive month of year-over-year declines. However, the decline was much steeper for Canadians returning from the U.S. this July compared to the previous year, at nearly 37 per cent. Last month marked the seventh consecutive month of year-over-year declines, StatCan said. 'In 2024, Canadian-resident trips to the United States totalled 39 million, representing 75 per cent of all Canadian-resident travel abroad,' according to another StatCan report published earlier this summer about travel to the U.S. 'However, recent data on foreign travel suggest that Canadians' travel sentiment toward their southern neighbour has been shifting in early 2025.' Although the data reflects a 'notable change in travel patterns,' StatCan said it is 'unclear whether the change is temporary or part of a more permanent shift.' As for air travel, the number of non-resident visitors who flew to Canada increased in July. There were 1.4 million of them — up by just over 3 per cent since the same time last year. While the bump was largely due to residents who came from overseas (up 5.6 per cent this year), American travellers were also up by just under 1 per cent. The highest number of U.S.-resident arrivals by air was 31,600 Americans on July 3, before the Independence Day long weekend in the U.S. Meanwhile, the number of Canadians returning home from abroad by air last month was down by 5.3 per cent compared to the previous year. In particular, Canadians flying back from the U.S. also decreased by nearly 26 per cent since the same time last year. Canadian permanent residents will now have to pay 'visa integrity fee' to enter U.S. Here's what it is An American sent to Canada was shocked by how furious Canadians are at the U.S. Our website is the place for the latest breaking news, exclusive scoops, longreads and provocative commentary. Please bookmark and sign up for our daily newsletter, Posted, here.
Yahoo
7 minutes ago
- Yahoo
Paramount Skydance (PSKY) Soars 60% to New High. Time to Book Gains?
We recently published . Paramount Skydance Corp. (NASDAQ:PSKY) is one of the best-performing stocks on Wednesday. Paramount Skydance extended its rally to touch a new high on Wednesday, finishing up by 36.74 percent at $15 apiece, with a former hedge fund manager calling it a 'meme' stock. In a social media post, Mad Money host and former hedge fund manager Jim Cramer said Paramount Skydance Corp. (NASDAQ:PSKY) is a 'meme stock' given the company's small public float and unjustifiable rally amid the lack of fresh developments. Paramount Skydance Corp. (NASDAQ:PSKY) climbed by as high as 60 percent at intra-day trading to hit $17.53 before paring gains to finish slightly lower during the session. In recent news, the company bagged a new $7.7-billion deal to exclusively air the Ultimate Fighting Championship (UFC) on Paramount+ for seven years beginning in 2026. The deal would include UFC's full slate of 13 marquee numbered events and 30 Fight Nights through its direct-to-consumer streaming platform, Paramount+, with select numbered events to be simulcast on CBS. cellanr, CC BY-SA 2.0 , via Wikimedia Commons As part of the agreement, Paramount Skydance Corp. (NASDAQ:PSKY) will move UFC away from the existing Pay-Per-View model and make the latter available at no additional cost to Paramount+ subscribers in the US. It also intends to explore UFC rights outside the US in the future. While we acknowledge the potential of PSKY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 minutes ago
- Yahoo
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data